BreaCLipeMD

Hematologic Oncology

Professor, Internal Medicine, University of Rochester

Dr. Lipe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
601 Elmwood Ave
# 320
Rochester, NY 14642
Phone+1 585-275-5823

Fax+1 585-273-1051

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2005 - 2008
Albany Medical CollegeClass of 2005

Denosumab for Smoldering Multiple Myeloma Start of enrollment: 2019 Apr 19
Active, not recruiting
Phase 2
Selinexor and Backbone Treatments of Multiple Myeloma Patients Start of enrollment: 2015 Oct 01
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma Start of enrollment: 2023 Aug 21
Recruiting
Phase 2
Roles: Contact, Principal Investigator

PubMed

Abstracts/Posters

Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
Brea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Brea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Brea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
Brea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy
Brea C. Lipe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Picking Induction Regimens Based on Disease Risk
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Survivorship Plan for Multiple MyelomaDecember 3rd, 2022
For Newly Diagnosed Myeloma, Are Four Drugs Better Than Three?December 1st, 2021
Clinical Trials Gave Wilmot Multiple Myeloma Patient 18 Years - and He's Not Done CountingMay 20th, 2021
Join now to see all